Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Bellinvia

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Expert Review of Neurotherapeutics|March 5, 2019
Identifying risk factors for cognitive issues in multiple sclerosisMaria Pia Amato, Elio Prestipino, Angelo Bellinvia
Expert Opinion on Pharmacotherapy|December 21, 2022
Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosisAngelo Bellinvia, Emilio Portaccio, Maria Pia Amato
Brain Sciences|April 3, 2021
Cognitive Issues in Pediatric Multiple SclerosisEmilio Portaccio, Ermelinda De Meo, Angelo Bellinvia, et al.
Journal of Oral & Facial Pain and Headache|June 1, 2026
An exploration of possible future non-pharmacological multidisciplinary treatments to potentiate withdrawal strategy and recovery from medication overuse headache (MOH): a narrative reviewMarco Balordi, Nicholas Diani, Mattia Sinatra, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 1, 2020
Experience with rituximab therapy in a real-life sample of multiple sclerosis patientsAngelo Bellinvia, Elio Prestipino, Emilio Portaccio, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 2, 2022
Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapiesAngelo Bellinvia, Maria Grazia Aprea, Emilio Portaccio, et al.
Brain Sciences|November 27, 2021
Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and PrognosisMattia Fonderico, Emilio Portaccio, Lorenzo Razzolini, et al.
Multiple Sclerosis and Related Disorders|June 23, 2020
A new paraplegin mutation in a patient with primary progressive multiple sclerosisAngelo Bellinvia, Luisa Pastò, Claudia Niccolai, et al.
Brain Sciences|October 23, 2021
Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case SeriesMarco Allinovi, Angelo Bellinvia, Francesco Pesce, et al.
Frontiers in Neurology|April 5, 2021
The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple SclerosisEmilio Portaccio, Angelo Bellinvia, Elio Prestipino, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Expert Review of Neurotherapeutics|March 5, 2019
Identifying risk factors for cognitive issues in multiple sclerosisMaria Pia Amato, Elio Prestipino, Angelo Bellinvia
Expert Opinion on Pharmacotherapy|December 21, 2022
Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosisAngelo Bellinvia, Emilio Portaccio, Maria Pia Amato
Brain Sciences|April 3, 2021
Cognitive Issues in Pediatric Multiple SclerosisEmilio Portaccio, Ermelinda De Meo, Angelo Bellinvia, et al.
Journal of Oral & Facial Pain and Headache|June 1, 2026
An exploration of possible future non-pharmacological multidisciplinary treatments to potentiate withdrawal strategy and recovery from medication overuse headache (MOH): a narrative reviewMarco Balordi, Nicholas Diani, Mattia Sinatra, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 1, 2020
Experience with rituximab therapy in a real-life sample of multiple sclerosis patientsAngelo Bellinvia, Elio Prestipino, Emilio Portaccio, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 2, 2022
Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapiesAngelo Bellinvia, Maria Grazia Aprea, Emilio Portaccio, et al.
Brain Sciences|November 27, 2021
Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and PrognosisMattia Fonderico, Emilio Portaccio, Lorenzo Razzolini, et al.
Multiple Sclerosis and Related Disorders|June 23, 2020
A new paraplegin mutation in a patient with primary progressive multiple sclerosisAngelo Bellinvia, Luisa Pastò, Claudia Niccolai, et al.
Brain Sciences|October 23, 2021
Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case SeriesMarco Allinovi, Angelo Bellinvia, Francesco Pesce, et al.
Frontiers in Neurology|April 5, 2021
The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple SclerosisEmilio Portaccio, Angelo Bellinvia, Elio Prestipino, et al.
Pageof 3